Rules-Based Medicine and Multiplex Biosciences Merge.Merger Extends R&D Capabilities and Product Expertise; Expands Customer Base AUSTIN -- Rules-Based Medicine, Inc. (RBM RBM Roll Back Malaria (global partnership to reduce malaria) RBM Results Based Management RBM Reserve Bank of Malawi RBM Risk Based Maintenance RBM Reliability Based Maintenance RBM Reticular Basement Membrane RBM Radiation Belt Monitor ), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has merged with Lake Placid Lake Placid, village (1990 pop. 2,485), Essex co., NE N.Y.; settled 1850, inc. 1900. In the Adirondack Mts. at an altitude of 1,800 ft (549 m), the village surrounds Mirror Lake. It is a famous resort and sports center. , New York-based Multiplex Biosciences, Inc. to extend its research and development capability in multiplexed assay product development and expand its customer base. The combined company will operate under the Rules-Based Medicine name with headquarters located in Austin, Texas. Multiplex Bioscience employees will continue to work in Lake Placid, with immediate growth planned at that facility. "With the development of over 200 new assays scheduled in the next 18 months, Multiplex Bioscience is a strategically important addition to Rules-Based Medicine," said Craig Benson Craig Benson (born New York City, October 8, 1954) came to public attention by founding Cabletron Systems, now known as Enterasys Networks that became one of the largest employers in New Hampshire, and was governor of the state from January 2003 to January 2005. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Rules-Based Medicine. "RBM is in high-growth mode and we value the unique capabilities and expertise that the world-class Multiplex Bioscience scientists bring to our team as we accelerate our product development efforts." "We are pleased to join forces with the Rules-Based Medicine team," said Dominic Eisinger, Ph.D., president of Multiplex Biosciences. "Its customer base and growth are a testament to its leadership position. This merger opens opportunities for us to benefit from RBM's reinvestment Reinvestment Using dividends, interest and capital gains earned in an investment or mutual fund to purchase additional shares or units, rather than receiving the distributions in cash. 1. In terms of stocks, it is the reinvestment of dividends to purchase additional shares. and business growth strategy and continue our advancements in multiplex assay product development in Lake Placid." About Multiplex Biosciences Multiplex Biosciences, Inc. (www.multiplexbiosciences.com) provides contract multiplex immunoassay Immunoassay An assay that quantifies antigen or antibody by immunochemical means. The antigen can be a relatively simple substance such as a drug, or a complex one such as a protein or a virus. development, validation and manufacturing services to pharmaceutical companies, biotech firms and academic research institutions, and develops its own line of multiplex products. The company was founded in 2006 and is wholly owned by Dominic Eisinger and Laurie Stephen, former senior managers at Upstate Cell Signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as Solutions, now part of Millipore Corporation For other uses, see Millipore. Millipore Corporation (NYSE: MIL) founded in 1954, listed among the S&P 500 since the early 1990s, is an international biosciences company, known widely for its micrometer pore-size filters and tests. . About Rules-Based Medicine Rules-Based Medicine is a biomarker testing laboratory delivering reproducible quantitative multiplexed immunoassay data for the life sciences industry. RBM's multi-analyte profiles (MAPs) measure up to hundreds of proteins from a small volume in multiple sample types and multiple species. These MAPs provide a comprehensive and cost-effective evaluation of the protein expression patterns that are critical to applications such as drug safety and efficacy, disease diagnosis and disease modeling. More information is located at www.rbmmaps.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion